Alleviating common cold and influenza symptoms with molecular hydrogen
A method for alleviating, preventing or treating symptoms of a viral infection such as common cold and flu, comprising administering to a subject in need thereof at least one solid form that releases molecular hydrogen upon exposure to the subject's gastric juice.
1. A method of treating symptoms of a viral infection, comprising:
administering a plurality of ingestible hydrogen-generating solid forms to a subject experiencing an onset of one or more of symptoms of the viral infection, wherein:
the administering occurs within 24 hours of the onset of the symptoms,
the viral infection is selected from influenza and common cold,
the symptoms of the viral infection are selected from one or more of fever, headache, sore throat, nasal congestion, cough, and myalgia,
each of the plurality of solid forms is configured to release at least 0.83 mg of molecular hydrogen upon exposure to the gastric juice of the subject,
each of the plurality of solid forms is administered in the absence of pre-administration dilution in water or other liquid, and
two solid forms of the plurality of solid forms are administered every two hours at least four times such that a total amount of molecular hydrogen administered to the subject is at least 6.6 mg.
2. The method of claim 1 , wherein the method generates at least 10 mL of molecular hydrogen upon exposure to the gastric juice of the subject.
3. The method of claim 1 , wherein each of the plurality of solid forms is capable of generating at least 1.2 mg of molecular hydrogen.
4. The method of claim 1 , wherein each of the plurality of solid forms is capable of generating at least 1.6 mg of molecular hydrogen.
5. The method of claim 1 , wherein the plurality of solid forms are administered to deliver from about 6.6 mg to about 8.5 mg of molecular hydrogen to the subject.
6. The method of claim 1 , wherein the plurality of solid forms are administered to the subject in a dry form.
7. The method of claim 1 , comprising reducing a probability of the symptoms of the viral infection by at least 50% after 48 hours of the beginning of the administration of at least one of the hydrogen-generating solid forms.
8. The method of claim 1 , wherein the treating of the symptoms of the viral infections comprises treating Multiple Organ Dysfunction Syndrome.
9. The method of claim 1 , wherein the symptoms further comprise an acute upper respiratory infection.
10. The method of claim 1 , wherein the symptoms further comprise one or more of those of Table 1.
11. The method of claim 1 , wherein a solid form of the solid forms comprise a pill, tablet, capsule, powder, or granule.